Review article:

BERBERINE:
INS AND OUTS OF A NATURE-MADE PCSK9 INHIBITOR

Sarina Ataei¹, Prashant Kesharwani², Amirhossein Sahebkar¹,³,⁴,⁵*

¹ Applied Biomedical Research Center, Mashhad University of Medical Sciences, Mashhad, Iran
² Department of Pharmaceutics, School of Pharmaceutical Education and Research, Jamia Hamdard, New Delhi, India
³ Biotechnology Research Center, Pharmaceutical Technology Institute, Mashhad University of Medical Sciences, Mashhad, Iran
⁴ School of Medicine, The University of Western Australia, Perth, Australia
⁵ Department of Biotechnology, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran

* Corresponding author: Amirhossein Sahebkar, Department of Biotechnology, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran.
E-mail: sahebkara@mums.ac.ir; amir_saheb2000@yahoo.com

https://dx.doi.org/10.17179/excli2022-5234

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/).

ABSTRACT

Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a secreted protein and a critical regulator of low-density lipoprotein-cholesterol (LDL-C) through inducing degradation of the LDL receptor (LDLR) within the hepatocyte lysosome. PCSK9 deficiency significantly improves the survival rate of cardiovascular disease (CVDs) patients. Up to now, various PCSK9 inhibition approaches have been tested. However, the currently available PCSK9 inhibitors' widespread use is limited due to their inconvenient method of administration and high cost. On the other hand, inhibiting PCSK9 with nutraceuticals is safe and affordable. The plant-derived compound berberine has shown anti-PCSK9 activity in several studies. Berberine is an isoquinoline quaternary alkaloid of phyto origin. Berberine treatment boosts the hepatic expression of LDLRs, while decreasing the expression and secretion of the LDLR modulator PCSK9. The current review presents a collection of in vitro and in vivo studies investigating berberine's effects on PCSK9 mRNA expression, protein level, and function.

Keywords: Berberine, PCSK9, hypercholesterolemia, phytomedicine, dyslipidemia

INTRODUCTION

Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a key regulator of low-density lipoprotein cholesterol (LDL-C). PCSK9 is mainly expressed by hepatic cells and secreted into the bloodstream. Following its discovery in 2003, it has been studied extensively in cholesterol homeostasis and cardiovascular biology (Seidah et al., 2014). PCSK9's role in cholesterol metabolism was recognized in two French families with the clinical phenotype of dominant autosomal familial hypercholesterolemia and mutations in the PCSK9 gene encoding the protein.
PCSK9, not previously associated with cholesterol metabolism. With this discovery, interest in PCSK9 protein began to grow, and it is now known to be a highly polymorphic gene (Ascaso, 2016).

PCSK9 is most well known for its effect on low-density lipoprotein receptor (LDLR) in hepatocytes, representing the primary pathway by which LDL-C is cleared from the bloodstream (Peterson et al., 2008; Zhang et al., 2007). In the intracellular pathway, which is comparatively faster, PCSK9 binds to the EGF-A domain of the newly generated LDLR in the trans-Golgi network, where the PCSK9-LDLR complex is directed to the lysosome (Poirier et al., 2009). In the extracellular pathway, the secreted PCSK9 binds to the LDLR's EGF-A domain on the surface of hepatocytes and chaperones it to the lysosome via clathrin-mediated endocytosis (Peterson et al., 2008; Qian et al., 2007) (Figure 1a). Since normal recycling of LDLR to the hepatocyte surface depends on the EGF-A domain, PCSK9's binding to this domain inhibits the LDLR from being recycled to the cell surface and instead promotes lysosomal degradation of the LDLR (Atar et al., 2022). It is possible for LDLRs not bound to PCSK9 to be recirculated more than 100 times (Atar et al., 2022). As a result of PCSK9 activity, the LDL-C removal from the bloodstream by LDLRs is reduced, and the vulnerability to atherosclerotic cardiovascular diseases (ACVDs) is increased (Peterson et al., 2008; Zhang et al., 2007). Decreasing LDLR by PCSK9 leads to hyperlipidemia associated with numerous cardiovascular complications. Particularly, macrophages' uptake and accumulation of lipids in the vessel wall and the formation of foamy macrophages contribute to the development of atheromas (Sundararaman et al., 2021). Clinically, PCSK9 deficiency significantly improves the survival rate of cardiovascular disease (CVD) patients (Benn et al., 2010; Cohen et al., 2005, 2006). In light of PCSK9's importance in regulating LDL-C and LDLR metabolism and the safety of inhibiting it, PCSK9 has gained interest as a therapeutic target (Catapano and Papadopoulos, 2013). Through PCSK9 pharmacological inhibition, the LDLR action would be prolonged, improving LDL-C clearance and lowering plasma LDL-C levels (Costet et al., 2008).

**PCSK9 INHIBITORS AND THEIR CURRENT LIMITATIONS**

Various approaches have been developed to inhibit PCSK9, including monoclonal antibodies (mAbs), gene-silencing or editing technologies, such as antisense oligonucleotides, and small interfering RNA (siRNA)s; small-molecule inhibitors; clustered regularly interspaced short palindromic repeats (CRISPR)/Cas9 platform; modified binding proteins such as adnectins; mimetic peptides; and vaccination (Ito and Santos, 2017; Nishikido and Ray, 2019). The most extensively studied approach is the mAbs that target plasma PCSK9 and block PCSK9/LDLR interaction. Studies have shown that inhibition of PCSK9 by monoclonal antibodies significantly decreases LDL-C levels and reduces CVD incidence (Catapano and Papadopoulos, 2013; Do et al., 2013; Sahebkar and Watts, 2013a). Therefore far, two monoclonal antibodies (alirocumab and evolocumab) have been approved by European Medicines Agency (EMA) and Food and Drug Administration (FDA) for treating patients with hypercholesterolemia in 2015 and have been successfully used in clinics alone or combined with statin (Dixon et al., 2019; Kereiakes et al., 2015; Merćep et al., 2022; Raal et al., 2015; Sabatine et al., 2015). Statins are the most widely administered cholesterol-lowering agents with several pleiotropic effects (Bahrami et al., 2018 Bland et al., 2022; Dehnavi et al., 2021; Khalifeh et al., 2021; Shakour et al., 2020; Vahedian-Azimi et al., 2021). These drugs act through increasing the expression of hepatic LDLR while concurrently increasing PCSK9 expression, suggesting that their effect on PCSK9 may decrease the therapeutic effect of statins (Sahebkar et al., 2015). Moreover, inclisiran, a novel siRNA-based PCSK9 silencer, has recently
been approved by the EMA and FDA and has been proven to reduce LDL-C among patients at high risk of cardiovascular diseases (Cicero et al., 2022; Ray et al., 2017). siRNAs target intracellular PCSK9 (Ochin and Garelnabi, 2018). However, the administration method for these two classes of therapeutics is via the parenteral route, which is inconvenient and limits their widespread use, especially considering the chronicity of LDL-C-associated ACVD (Ochin and Garelnabi, 2018). This feature could make it difficult for patients to comply with treatment. Moreover, the treatment procedure of administering anti-PCSK9 antibodies has several other limitations. Including the short half-life of mAbs in vivo, neutralizing antibody production, and requiring multiple injections at high doses may impose a psychological and financial burden on patients (Galabova et al., 2014; Toth et al., 2020). They are characteristically protein in nature. Thus, pathologic intolerance or physiological tolerance to them during prolonged chronic use could arise due to increased clearance by the reticuloendothelial system or induction of hypersensitivity by the adaptive immune system, respectively (Ochin and Garelnabi, 2018). Given all these, specific nutraceuticals might be worth considering as supportive treatments for lipid-lowering (Banach et al., 2018; Fan et al., 2021; Ochin and Garelnabi, 2018). In several previous studies, traditional Chinese medicine has been demonstrated as a strategy to prevent and treat atherosclerosis (Ting-Ting et al., 2019; Zhang et al., 2019).

**WHAT IS BERBERINE, AND HOW DOES IT LOWER CHOLESTEROL?**

Berberine (BBR, C₂₀H₁₈N₂O₅⁺) is a quaternary ammonium salt derived from isoquinoline alkaloids, widely used in Ayurvedic and Chinese medicine due to its favorable clinical and safety profile (Jin et al., 2016; Ju et al., 2018; Lin and Zhang, 2018; Tillhon et al., 2012). It belongs to the class of protoberberines found in several plants, including *Berberis vulgaris*, *Coptis Chinensis*, and *Berberis aristata*, or obtained through total synthesis (Huang et al., 2011; Imanshahidi and Hosseinzadeh, 2008; Kong et al., 2004). Considering the latest advances in pharmacological research, BBR appears to be one of the most promising natural product-derived drugs for treating cardiovascular, renal, and metabolic diseases (CVMDs) (Feng et al., 2019; Bagherniya et al., 2018; Talebi et al., 2020; Yaribeygi et al., 2021). The natural cholesterol-lowering agent, berberine, has been found to have antidysslipidemic properties (Kong et al., 2004). It can lower both adipogenesis and lipid synthesis (Choi et al., 2006). Berberine directly facilitates the stabilization of LDLR mRNA by activating regulatory proteins downstream of the extracellular signal-regulated kinase (ERK) pathway; those regulatory proteins interact with the proximal sequences in the 3’ untranslated region (UTR) of LDLR mRNA, and by activating Jun amino-terminal kinase (JNK)-dependent pathways (Abidi et al., 2005; Li et al., 2009). In addition, berberine has demonstrated anti-PCSK9 effects by ubiquitination and degradation of hepatocyte nuclear factor 1 alpha (HNF1α), an essential cofactor for sterol regulatory element-binding protein-2 (SREBP-2) in PCSK9 transcriptional regulation (Li et al., 2009; Shafabakhsh et al., 2021). Studies have demonstrated that berberine is a trans-activator of PCSK9 expression and inhibits its transcription via the HNF1 binding site of the PCSK9 promoter (Shafabakhsh et al., 2021). Berberine improved HNF1α protein degradation as well, leading to promoting the expression of LDLR and limiting its degradation, resulting in greater clearance of LDL (Dong et al., 2015; Fan et al., 2021; Ochin and Garelnabi, 2018) (Figure 1b). Many studies have shown berberine’s effect on PCSK9 expression, suggesting PCSK9 may be a target for berberine (Ochin and Garelnabi, 2018). In the following section, we discuss several *in vitro* and *in vivo* studies showing berberine-mediated modulation of PCSK9 mRNA expression, protein level, and function (Tables 1-3).
Figure 1: PCSK9 functions with or without presence of berberine. **a. PCSK9 mechanism of action.**

PCSK9 is secreted from the endoplasmic reticulum to the Golgi apparatus and subsequently from the trans-Golgi network into the medium. A secreted form of PCSK9 binds to LDLR on the hepatocyte surface and facilitates degradation of the PCSK9-LDLR-LDL complex (extracellular pathway); PCSK9 directly binds to the newly generated LDLR in the trans-Golgi network, where the PCSK9-LDLR complex is directed to the lysosome (intracellular pathway).

**b. PCSK9 mechanism of action, in the presence of berberine.** Berberine directly facilitates the stabilization of LDLR mRNA. It inhibits hepatocyte nuclear factor 1 alpha (HNF1α) protein, thereby decreasing PCSK9 expression, promoting the expression of LDLR, and limiting its degradation, resulting in more significant clearance of LDL.
Table 1: Effect of berberine on PCSK9, LDLR, and LDL-C levels in experimental studies

| Subjects                              | BBR dose                        | PCSK9 alternation levels | LDLR and LDL-C alternation levels | Reference                       |
|---------------------------------------|---------------------------------|--------------------------|-----------------------------------|--------------------------------|
| HepG2 cells                           | 15 μg/ml (44 μM)                | -77% in mRNA            | +3 fold in mRNA                   | Cameron et al., 2008            |
| HepG2 cells                           | 20 μM                           | -30% at 12 h in mRNA,   | +1.8-3 folds in mRNA              | Li et al., 2009                 |
| LPS-induced dyslipidemic mice         | 10 or 30 mg/kg                  | Decrease in mRNA        | Increase in LDLR mRNA and protein, Decrease in plasma LDL-C | Xiao et al., 2012               |
| HFD rats                              | 400 mg/kg/d                     | Increase in plasma protein | Increase in LDLR mRNA and protein, Decrease in plasma LDL-C | Jia et al., 2014                |
| HFD rats                              | 156 mg/kg/d                     | Decrease in hepatic protein | Increase in LDLR protein, Decrease in plasma LDL-C | Liu et al., 2015                |
| HFD mice                              | 200 mg/kg/d                     | -46% in mRNA, -50% in serum protein | +67% in LDLR protein | Dong et al., 2015               |
| HFD hamsters                          | 100 mg/kg/d                     | -30% in serum protein   | ND                                 | Dong et al., 2015               |
| HepG2 cells                           | 40 μM                           | Decrease in mRNA and protein | ND                                 | Ochin and Garelnabi, 2018       |
| HepG2 cells                           | 10 μM                           | Decrease in mRNA        | Increase in LDLR mRNA             | Ochin and Garelnabi, 2018       |
| HepG2 cells                           | 150 μM                          | Decrease in mRNA        | Increase in LDLR mRNA             | Ochin and Garelnabi, 2018       |
| ApoE-/- mice fed with HFD             | 50 and 100 mg/kg/d              | Decrease in mRNA and hepatic protein | Increase in LDLR mRNA and protein, Decrease in LDL-C | Vahedian-Azimi et al., 2021     |
| HepG2 cells                           | 5, 25, and 50 μg/mL             | Decrease in protein     | Increase in LDLR protein          | Vahedian-Azimi et al., 2021     |
| HepG2 cells                           | 150 μM of BBR encapsulated nanoparticles in PVA surfactant nanoemulsion (BC-NP) | Decrease in mRNA and intercellular protein | Increase in mRNA | Ochin and Garelnabi, 2018       |
Table 2: Effect of berberine on PCSK9, LDLR, and LDL-C levels in combination with other nutraceuticals or medications in experimental studies

| Subjects                          | Intervention                                                                 | PCSK9 alternation levels | LDLR and LDL-C alternation levels | Reference                  |
|-----------------------------------|------------------------------------------------------------------------------|--------------------------|-----------------------------------|----------------------------|
| HepG2 cells                       | 15 μg/ml (44 μM) BBR+mevastatin                                             | -56% in mRNA             | +6 fold in LDLR mRNA              | Cameron et al., 2008       |
| HepG2 cells                       | 20 or 40 μM BBR+fluvastatin or lovastatin or simvastatin                    | -2 fold in mRNA          | ND                                | Li et al., 2009            |
| Patients with primary hypercholesterolemia with a history of STs intolerance or refusing STs treatment | Nutraceutical pill containing berberine (500 mg), policosanol (10 mg), and red yeast rice (200 mg) (for 6 months) | ND                        | -31.7% and 23.5% in LDL-C          | Pisciotta et al., 2012     |
| Patients with primary hypercholesterolemia with a history of STs intolerance or refusing STs treatment | Nutraceutical pill containing berberine (500 mg), policosanol, (10 mg) and red yeast rice (200 mg) combined with EZE (10 mg/day) (for 6 months) | ND                        | -37.1% in LDL-C                  | Pisciotta et al., 2012     |
| HeFH patients                     | Nutraceutical pill containing berberine (500 mg), policosanol (10 mg), and red yeast rice (200 mg) (for 6 months) | Suggested to be decreased (not reported) | -10.6% in LDL-C                  | Pisciotta et al., 2012     |
| Hypercholesteremic individuals    | Nutraceutical Formulation (berberine (200 mg), chitosan (10 mg), red yeast rice (3 mg monacolin K and 10 mg coenzyme Q)) (for 12 weeks) | Plasma levels remained stable | -20% in LDL-C                    | Spigoni et al., 2017       |
| patients suffering from polygenic hypercholesterolemia, characterized by a low/intermediate cardiovascular risk | Nutraceutical containing monacolin K+KA (1:1) (10 %), berberine (500 mg) and silymarin (for 2 months) | +25.6% in serum protein     | -27.5% in LDL-C                  | Formisano et al., 2020     |

Table 3: Effect of berberine derivatives and modified forms on PCSK9, LDLR, and LDL-C levels in experimental studies

| Subjects | Intervention                        | PCSK9 alternation levels | LDLR and LDL-C alternation levels | Reference                  |
|----------|-------------------------------------|--------------------------|-----------------------------------|----------------------------|
| HFD rats | 8-hydroxy-dihydro-berberine (Hdber) (78, 39, and 19.5 mg/kg/d) | Decrease in hepatic protein | Increase in LDLR protein, Decrease in plasma LDL-C | Liu et al., 2015          |
| HepG2 cells | 2,3-dimethoxy moiety, Compound 9K (5 and 10 μM) | Decrease in protein | Increase in LDLR protein | Fan et al., 2021          |
| C57BL/6J mice | 2,3-dimethoxy moiety, Compound 9K (5 μM) | Decrease in the liver and serum protein | ND | Fan et al., 2021          |
CELL CULTURE AND ANIMAL STUDIES

In a study by Cameron et al., berberine (44 μM) was shown to decrease PCSK9 mRNA by 77 % and PCSK9 protein levels by 87 % in HepG2 cells, which was associated with a 3-fold increase in LDLR mRNA expression (Cameron et al., 2008). They reported that this reduction was most likely caused by a decrease in PCSK9 gene transcription rather than an increase in PCSK9 mRNA degradation. Additionally, when HepG2 cells were simultaneously treated with berberine and mevastatin, the effect of mevastatin on PCSK9 mRNA was suppressed, and the amount of PCSK9 mRNA was decreased by 56 %; therefore, the LDLR-rising effect was enhanced. Compared with cells receiving mevastatin alone, there was a 1.4-fold rise in LDLR protein levels and a 6-fold increase in LDLR mRNA (Cameron et al., 2008). Similarly, in another study by Li et al. on HepG2 cells, 20 μM of berberine treatment decreased PCSK9 mRNA expression (Li et al., 2009). They detected a 30 % reduction at 12 h and a gradual decline in the mRNA level of PCSK9 in berberine-treated cells down to 23 % of untreated control at 48 h. On the other hand, they detected an increase in LDLR mRNA expression by 1.8-fold at four h and up to 3-fold at 24 h (Li et al., 2009). Moreover, they treated HepG2 cells with 20 μM or 40 μM of berberine in the absence or presence of 1 μM of fluvastatin, lovastatin, or simvastatin for 24 h and found that although statins independently increased PCSK9 mRNA levels above 2-fold of control, their inducing effects were not observed in cells simultaneously treated with berberine at both mentioned doses (Li et al., 2009). It also has been reported by Xiao et al. that administration of 10 or 30 mg/kg/day of berberine for four weeks prevented the induction of PCSK9 mRNA expression, attenuation of LDLR mRNA, and elevation of plasma LDL-C in C57BL/6 mice who were co-treated with 5 mg/kg/day LPS (Xiao et al., 2012). Nevertheless, in another study, Jia et al. examined the effects of berberine administration (400 mg/kg/day) for six weeks in HFD rats and obtained inconsistent results (Jia et al., 2014). They showed that berberine dramatically raises plasma levels of PCSK9. It raised the mRNA and protein expression levels of LDLR in the liver and lowered plasma LDL-C concentrations in HFD rats compared to control rats (Jia et al., 2014). Genetic polymorphisms may cause such variations in PCSK9 responsiveness to berberine in the PCSK9 and LDLR promoters, affecting how berberine interacts with the promoter and ultimately changing gene transcription (De Castro-Oros et al., 2016).

Liu et al. examined the effects of berberine (156 mg/kg/day) and 8-hydroxy-dihydroberberine (Hdber) (78, 39, and 19.5 mg/kg/day), a structurally modified version of berberine, on HFD rats (Liu et al., 2015). The two compounds markedly lowered the expression levels of PCSK9 protein, associated with elevated expression levels of LDL-R and a subsequent decline in serum LDL-C (total cholesterol) TC, and triglyceride (TG). In addition, rats in BBR and those treated with high doses of hdber (78 mg/kg/day) displayed significantly elevated HDL-C levels in their serum. They indicated that hdber could make similar effects as berberine when only 25 % of the original dosage of berberine needed were administered (Liu et al., 2015).

Dong et al., in another study, evaluated PCSK9 levels and hepatic LDLR expression changes in HFD mice and hamsters treated with 200 mg/kg/day and 100 mg/kg/day berberine, respectively (Dong et al., 2015). After 16 days of treatment with berberine, serum PCSK9 levels and its hepatic mRNA expression were reduced by 50 % and 46 %, respectively, in HFD mice; leading to increased protein levels of hepatic LDLR (67 %) and lowered serum cholesterol levels (TC and LDL-C) in HFD mice compared to controls (Dong et al., 2015). Furthermore, they evaluated the effect of berberine treatment on HFD hamsters with 100 mg/kg/day of berberine over seven days to evaluate its efficacy in other animal models. The hamsters in the treated group showed a reduction of 30 % in PCSK9 mRNA.
serum levels compared to the control group (Dong et al., 2015). Consistent with the results mentioned above, they reported significant reductions in mRNA and protein expression of PCSK9 levels in HepG2 cells after 16 and 24 h of berberine treatment (40 μM) (Dong et al., 2015).

In 2018, Ochin and Garelnabi published observations indicating an association between berberine release from PLGA-PEG-PLGA encapsulation polymer and the expression of PCSK9 mRNA and protein in a time-dependent manner (Ochin and Garelnabi, 2018). They demonstrated a significant down-regulation of PCSK9 mRNA in HepG2 cells treated with 150 μM (high-FD) and 10 μM (low-FD) concentrations of free berberine drug solution and 150 μM of berberine encapsulated nanoparticles in PVA surfactant nanoemulsion (BC-NP) during a 24-hour and 48-hour period (Ochin and Garelnabi, 2018). They showed that the cells treated with low FD showed the highest reduction in PCSK9 mRNA at the end of the 24-hour treatment period, closely followed by the cells treated with high-FD, and ultimately by the cells treated with BC-NP, while the untreated cells showed the most significant expression of PCSK9 mRNA (Ochin and Garelnabi, 2018). However, at the end of 48 hours, PCSK9 mRNA expression was significantly lower in cells treated with high-FD than in those treated with low-FD, whose levels had already risen (Ochin and Garelnabi, 2018). Compared to the same group of cells from the 24-hour treatment duration, the cells treated with BC-NP displayed a considerable reduction in PCSK9 mRNA, with levels almost similar to the low-FD cells from the 48-hour treatment duration (Ochin and Garelnabi, 2018). Moreover, the 24-hour treatment period revealed that Hep-G2 cells in the low concentration group of FD (FD-low) expressed PCSK9 protein at the lowest levels, this were followed by the expression level in the FD-high concentration group, and the BC-NP group has an expression level close to what the cells in the untreated group synthesize (Ochin and Garelnabi, 2018). Nevertheless, the 48-hour treatment period with equal berberine concentrations and forms demonstrates that PCSK9 expression levels and forms remains the same. On the other hand, the PCSK9 expression level in the BC-NP treated cell group was significantly decreased (Ochin and Garelnabi, 2018). In addition, after 48 hours of BC-NP, low-FD, or high-FD treatment with the same berberine concentrations, the authors also found a significant upregulation of LDLR mRNA expression (Ochin and Garelnabi, 2018).

In one of the most recent research, Fan et al. synthesized 40 berberine derivatives and evaluated them for their ability to suppress PCSK9 transcription in HepG2 cells, with berberine serving as the benchmark (Fan et al., 2021). Analysis of the structure-activity relationship suggested that the 2,3-dimethoxy moiety would favor activity. The most powerful activity among them, superior to berberine’s, was shown by 9k (Fan et al., 2021). Compound 9K (5 and 10 μM) significantly decreased the level of PCSK9 protein in HepG2 cells. 9k administrating (50 mg/kg) every day for four weeks also decreased PCSK9 protein levels in the liver and serum of C57BL/6J mice (Fan et al., 2021). Furthermore, they evaluated the effects of 9k on LDLR expression and LDL-C uptake in HepG2 cells (Fan et al., 2021). They showed that 9k treatment significantly upregulated LDLR protein levels in a dose-dependent manner. Moreover, compound 9k (20 μM) markedly promoted DiI-LDL uptake in a dose-dependent manner (5, 10, 20 μM) with a scale of 2–3 folds, which was much more effective than that of BBR (20 μM) (Fan et al., 2021).

Ma et al. (2021) published results indicating that BBR treatment at doses of 50 and 100 mg/kg/d could enhance lipid metabolism in the serum by significantly lowering total cholesterol (TC), triglyceride (TG), low-density lipoprotein (LDL-C), and increasing high-density lipoprotein cholesterol (HDL-C) levels in ApoE/-/- mice fed with HFD. Berberine could decrease PCSK9 mRNA and hepatic protein levels and increase LDLR mRNA and
protein in the liver of ApoE-/- mice fed with HFD (Vahedian-Azimi et al., 2021). They also showed that berberine at the mentioned doses decreased aorta atherosclerotic plaque and ameliorated lipid deposits in ApoE-/-mice fed with HFD (Vahedian-Azimi et al., 2021). Moreover, BBR (0, 5, 25, and 50 μg/mL) treatment of HepG2 cells led to increased LDLR protein expression and decreased PCSK9 protein expression through the extracellular signal-regulated kinase 1/2 (ERK1/2) pathway (Vahedian et al., 2021).

**CLINICAL STUDIES**

A clinical trial conducted by Pisciotta et al. investigated the impact of a nutraceutical pill containing berberine (500 mg), policosanol (10 mg), and red yeast rice (200 mg) in subjects with primary hypercholesterolemia (HCH) with a history of statins (STs) intolerance or refusing STs treatment (Pisciotta et al., 2012). Nutraceutical pill was found to lower LDL-C by 31.7% after six months of follow-up, which was more efficacious and better tolerated than ezetimibe (EZE) (Pisciotta et al., 2012). In the same study, supplementary treatment with nutraceutical pills in heterozygous hypercholesterolemia (HeFH) patients on stable STs or STs plus EZE resulted in a greater reduction of LDL-C (mean reduction of 10.5%). The reduction (37.1%) was even higher than doubling the dose of ST, and it was thought to be associated with an indirect, berberine-mediated inhibition of PCSK9 (Pisciotta et al., 2012).

A 12-week treatment with a nutraceutical formulation containing putative lipid-lowering compounds (berberine 200 mg, chitosan, red yeast rice) was effective in lowering plasma non-HDL-C (by ~15%) and LDL-C (by 20%) compared with placebo, according to a double-blind, randomized, placebo-controlled study (Spigoni et al., 2017). Notably, during the study, the PCSK9 plasma levels remained stable in individuals with hypercholesterolemia (Spigoni et al., 2017). Besides, three adverse effects were noted in the trial mentioned above, including duodenitis, Epstein-Barr virus infection, and an asymptomatic but considerable rise in creatine phosphokinase (after intense exercise) that necessitated hospitalization. Nevertheless, the intervention was well tolerated (Spigoni et al., 2017).

A combination of a nutraceutical with monacolin K (MonK)+KA (1:1), berberine (500 mg), and silymarin proved effective as a lipid-lowering agent with a large interindividual response variability, according to a pilot trial (Formisano et al., 2020). The result was comparable to what 10 mg of atorvastatin would have produced (Formisano et al., 2020). Besides, eight weeks of nutraceutical administration resulted in a significant +25.6% increase in serum PCSK9. They suggested that BBR activity may only partially suppress the PCSK9 increase when more bioavailable (Formisano et al., 2020). Ultimately, NUT administration inhibited serum-mediated foam cell formation, as shown in human macrophages (Formisano et al., 2020). The functional profile of lipoproteins with a probable antiatherogenic effect was improved by *ex vivo* NUT treatment (Formisano et al., 2020).

**CONCLUSION**

Berberine and berberine-like compounds have shown LDL-lowering effects in several studies and could significantly inhibit PCSK9 at both transcriptional and protein levels. Nevertheless, it must be noted that berberine cannot replace standard lipid-lowering therapy but may adjunctively help enhancing the activity of current therapies in reducing CV risk (Cicero et al., 2017). Combining berberine with other lipid-lowering nutraceuticals could reduce the required dosages of single components, leading to safety improvement. Berberine can be a beneficial adjunct to statin therapy since the latter is accompanied by an elevation of PCSK9 levels, which limit the efficacy of statins. It is, however, necessary to conduct high-quality randomized controlled trials to ensure berberine’s long-term efficacy in reducing CVD mortality and morbidity.
Conflict of interest
The authors declare no conflict of interest.

REFERENCES
Abidi P, Zhou Y, Jiang JD, Liu J. Extracellular signal-regulated kinase-dependent stabilization of hepatic low-density lipoprotein receptor mRNA by herbal medicine berberine. Arterioscler Thromb Vas Biol. 2005;25:2170-6. doi: 10.1161/01.ATV.000018761.16341.2b.

Ascaso JF. Inhibition of proprotease subtilisin/kexin type 9 in the treatment of hypercholesterolemia. ndocrinol Nutr. 2016;63:255-7. doi: 10.1016/j.endou.2016.02.002.

Atar D, Langslet G, Tonstad S. Do we need new lipid-lowering agents in the era of PCSK9 inhibitors? Recent advances. Kardiol Pol. 2022 May 6. doi: 10.33963/KP.a2022.0117. Epub ahead of print.

Baghermiya M, Nobili V, Blessos CN, Sahebkar A. Medicinal plants and bioactive natural compounds in the treatment of non-alcoholic fatty liver disease: A clinical review. Pharmacol Res. 2018;130:213-40. doi: 10.1016/j.phrs.2017.12.020.

Bahrami A, Parsamanesh N, Atkin SL, Banach M, Sahebkar A. Effect of statins on toll-like receptors: a new insight to pleiotropic effects. Pharmacol Res. 2018;135:230-8. doi: 10.1016/j.phrs.2018.08.014.

Banach M, Patti AM, Giglio RV, Cicero AF, Atanasov AG, Bajraktari G, et al. The role of nutraceuticals in statin intolerant patients. J Am Coll Cardiol. 2018;72:96-118.

Benn M, Nordestgaard BG, Grande P, Schnohr P, Tybjærg-Hansen A. PCSK9 R46L, low-density lipoprotein cholesterol levels, and risk of ischemic heart disease: 3 independent studies and meta-analyses. J Am Coll Cardiol. 2010;55:2833-42.

Bland AR, Payne FM, Ashton JC, Jamialahmadi T, Sahebkar A. The cardioprotective actions of statins in targeting mitochondrial dysfunction associated with myocardial ischaemia-reperfusion injury. Pharmacol Res. 2022;175:105986. doi: 10.1016/j.phrs.2021.105986.

Cameron J, Ranheim T, Kulseth MA, Leren TP, Berge KE. Berberine decreases PCSK9 expression in HepG2 cells. Atherosclerosis. 2008;201:266-73.

Catapano A, Papadopoulos N. The safety of therapeutic monoclonal antibodies: implications for cardiovascular disease and targeting the PCSK9 pathway. Atherosclerosis. 2013;228:18-28.

Choi B-H, Ahn I-S, Kim Y-H, Park J-W, Lee S-Y, Hyun C-K, et al. Berberine reduces the expression of adipogenic enzymes and inflammatory molecules of 3T3-L1 adipocyte. Exp Mol Med. 2006;38:599-605.

Cicero AF, Colletti A, Bajraktari G, Descamps O, Djuric DM, Ezhot M, et al. Lipid-lowering nutraceuticals in clinical practice: position paper from an International Lipid Expert Panel. Nutr Rev. 2017;75:731-67.

Cicero AF, Fogacci F, Zambon A, Toth PP, Borghi C. Efficacy and safety of inclisiran a newly approved FDA drug: a systematic review and pooled analysis of available clinical studies. Am Heart J Plus Cardiol Res Pract. 2022;13:100127.

Cohen J, Pertsemlidis A, Kotowski IK, Graham R, Garcia CK, Hobbs HH. Low LDL cholesterol in individuals of African descent resulting from frequent nonsense mutations in PCSK9. Nat Genet. 2005;37:161-5.

Cohen JC, Boerwinkle E, Mosley TH Jr, Hobbs HH. Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. N Engl J Med. 2006;354:1264-72.

Costet P, Krempf M, Cariou B. PCSK9 and LDL cholesterol: unravelling the target to design the bullet. Trends Biochem Sci. 2008;33:426-34.

De Castro-Oros I, Sola R, Valls RM, Brea A, Mozas P, Puzo J, et al. Genetic variants of LDLR and PCSK9 associated with variations in response to antihypercholesterolemic effects of armolipid plus with berberine. PLoS One. 2016;11(3):e0150785.

Dehnavi S, Kiani A, Sadeghi M, Biregani AF, Banach M, Atkin SL, et al. Targeting AMPK by statins: a potential therapeutic approach. Drugs. 2021;81:923-33. doi: 10.1007/s40265-021-01510-4.

Dixon DL, Pamulapati LG, Bucheit JD, Sisson EM, Smith SR, Kim CJ, et al. Recent updates on the use of PCSK9 inhibitors in patients with atherosclerotic cardiovascular disease. Curr Atheroscler Rep. 2019;21(5):16. doi: 10.1007/s11883-019-0778-6.

Do RQ, Vogel RA, Schwartz GG. PCSK9 inhibitors: potential in cardiovascular therapeutics. Curr Cardiol Rep. 2013;15(3):345.

Dong B, Li H, Singh AB, Cao A, Liu J. Inhibition of PCSK9 transcription by berberine involves down-regulation of hepatic HNF1α protein expression through the ubiquitin-proteasome degradation pathway. J Biol Chem. 2015;290:4047-58.
Fan T-Y, Yang Y-X, Zeng Q-X, Wang X-L, Wei W, Guo X-X, et al. Structure–activity relationship and biological evaluation of berberine derivatives as PCSK9 down-regulating agents. Bioorg Chem. 2021;113:104994.

Feng X, Sureda A, Jafari S, Memariani Z, Tewari D, Annunziata G, et al. Berberine in cardiovascular and metabolic diseases: from mechanisms to therapeutics. Theranostics. 2019;9(7):1923.

Formisano E, Pasta A, Cremonini AL, Favari E, Ronca A, Carbone F, et al. Efficacy of nutraceutical combination of monacolin K, berberine, and silymarin on lipid profile and PCSK9 plasma level in a cohort of hypercholesterolemic patients. J Med Food. 2020;23:658-66. doi: 10.1089/jmf.2019.0168.

Galabova G, Brunner S, Winsauer G, Juno C, Wanko B, Mairhofer A, et al. Peptide-based anti-PCSK9 vaccines-an approach for long-term LDLc management. PLoS One. 2014;9(12):e114469.

Huang Z, Zeng Y, Lan P, Sun P, Chen W. Advances in structural modifications and biological activities of berberine: an active compound in traditional Chinese medicine. Mini Rev Med Chem. 2011;11:1122-9. doi: 10.2174/138955711797655362.

Imanshahidi M, Hosseinazadeh H. Pharmacological and therapeutic effects of Berberis vulgaris and its active constituent, berberine. Phytother Res. 2008;22:999-1012.

Ito MK, Santos RD. PCSK9 inhibition with monoclonal antibodies: a modern management of hypercholesterolemia. J Clin Pharmacol. 2017;57(1):7-32.

Jia Y-J, Xu R-X, Sun J, Tang Y, Li J-J. Enhanced circulating PCSK9 concentration by berberine through SREBP-2 pathway in high fat diet-fed rats. J Transl Med. 2014;12:103.

Jin Y, Khadka DB, Cho W-J. Pharmacological effects of berberine and its derivatives: a patent update. Expert Opin Ther Patents. 2016;26:229-43.

Ju J, Li J, Lin Q, Xu H. Efficacy and safety of berberine for dyslipidemias: A systematic review and meta-analysis of randomized clinical trials. Phytomedicine. 2018;50:25-34.

Kereiakes DJ, Robinson JG, Cannon CP, Lorenzato C, Pordy R, Chaudhari U, et al. Efficacy and safety of the proprotein convertase subtilisin/kexin type 9 inhibitor alirocumab among high cardiovascular risk patients on maximally tolerated statin therapy: the ODYSSEY COMBO I study. Am Heart J. 2015;169:906-15.e13.

Khalifeh M, Penson PE, Banach M, Sahebkar A. Statins as anti-pyroptotic agents. Arch Med Sci. 2021;17:1414-7. doi: 10.5114/amis/141155.

Kong W, Wei J, Abidi P, Lin M, Inaba S, Li C, et al. Berberine is a novel cholesterol-lowering drug working through a unique mechanism distinct from statins. Nat Med. 2004;10:1344-51.

Li H, Dong B, Park SW, Lee H-S, Chen W, Liu J. Hepatocyte nuclear factor 1α plays a critical role in PCSK9 gene transcription and regulation by the natural hypocholesterolemic compound berberine. J Biol Chem. 2009;284:28885-95.

Lin X, Zhang N. Berberine: Pathways to protect neurons. Phytother Res. 2018;32:1501-10.

Liu D-I, Xu L-j, Dong H, Chen G, Huang Z-y, Zou X, et al. Inhibition of proprotein convertase subtilisin/kexin type 9: A novel mechanism of berberine and 8-hydroxy dihydroberberine against hyperlipidemia. Chin J Integr Med. 2015;21:132-8.

Ma C-Y, Shi X-Y, Wu Y-R, Zhang Y, Yao Y-H, Qu H-L, et al. Berberine attenuates atherosclerotic lesions and hepatic steatosis in ApoE-/- mice by down-regulating PCSK9 via ERK1/2 pathway. Ann Transl Med. 2021;9(20):1517. doi: 10.21037/atm-20-8106.

Mercép I, Friščič N, Strikić D, Reiner Ž. Advantages and disadvantages of inclisiran: a small interfering ribonucleic acid molecule targeting PCSK9 - a narrative review. Cardiovasc Ther. 2022;2022:8129513.

Nishikido T, Ray KK. Non-antibody approaches to proprotein convertase subtilisin kexin 9 inhibition: siRNA, antisense oligonucleotides, adnectins, vaccination, and new attempts at small-molecule inhibitors based on new discoveries. Front Cardiovasc Med. 2019;5:199.

Ochin CC, Garelnabi M. Berberine encapsulated PLGA-PEG nanoparticles modulate PCSK-9 in HepG2 cells. Cardiovasc Hematol Disord Drug Targets. 2018;18:61-70. doi: 10.2174/1871529X18666180201130340.

Peterson AS, Fong LG, Young SG. Errata. PCSK9 function and physiology. J Lipid Res. 2008;49:1595-9.

Pisciotta L, Belloccchio A, Bertolini S. Nutraceutical pill containing berberine versus ezetimibe on plasma lipid pattern in hypercholesterolemic subjects and its additive effect in patients with familial hypercholesterolemia on stable cholesterol-lowering treatment. Lipids Health Dis. 2012;11:123. doi: 10.1186/1476-511X-11-123.
Poirier S, Mayer G, Poupon V, McPherson PS, Desjardins R, Ly K, et al. Dissection of the endogenous cellular pathways of PCSK9-induced low density lipoprotein receptor degradation: evidence for an intracellular route. J Biol Chem. 2009;284:28856-64.

Qian Y-W, Schmidt RJ, Zhang Y, Chu S, Lin A, Wang H, et al. Secreted PCSK9 downregulates low density lipoprotein receptor through receptor-mediated endocytosis. J Lipid Res. 2007;48:1488-98.

Raal FJ, Stein EA, Dufour R, Turner T, Civeira F, Burgess L, et al. PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial. Lancet. 2015;385(9965):331-40.

Ray KK, Landmesser U, Leiter LA, Kallend D, Dufour R, Karakas M, et al. Inclisiran in patients at high cardiovascular risk with elevated LDL cholesterol. N Engl J Med. 2017;376:1430-40.

Sabatine MS, Giugliano RP, Wiviott SD, Raal FJ, Blom DJ, Robinson J, et al. Efficacy and safety of evolocumab in reducing lipids and cardiovascular events. N Engl J Med. 2015;372:1500-9.

Sahebkar A, Watts GF. New LDL-cholesterol lowering therapies: Pharmacology, clinical trials, and relevance to acute coronary syndromes. Clin Ther. 2013a;35:1082-98. doi: 10.1016/j.clinthera.2013.06.019.

Sahebkar A, Watts GF. New therapies targeting apoB metabolism for high-risk patients with inherited dyslipidaemias: what can the clinician expect? Cardiovasc Drugs Ther. 2013b;27:559-67.

Sahebkar A, Simental-Mendia L, Guerrero-Romero F, Golleljye D, Watts G. Effect of statin therapy on plasma proprotein convertase subtilisin kexin 9 (PCSK9) concentrations: a systematic review and meta-analysis of clinical trials. Diabetes Obes Metab. 2015;17:1042-55. doi: 10.1111/dob.12536.

Seidah NG, Awan Z, Chrétien M, Mbikay M. PCSK9: a key modulator of cardiovascular health. Circ Res. 2014;114:1022-36.

Shafabakhsh R, Reiner Z, Hallajzadeh J, Mirsafaei L, Asemi Z. Are anti-inflammatory agents and nutraceuticals-novel inhibitors of PCSK9? Crit Rev Food Sci Nutr. 2021;61:325-36.

Shakour N, Ruscica M, Hadizadeh F, Cirtori C, Banach M, Jamialahmadi T, et al. Statins and C-reactive protein: In silico evidence on direct interaction. Arch Med Sci. 2020;16:1432-9. doi: 10.5114/AOMS.2020.100307.

Spigoni V, Aldigeri R, Antonini M, Micheli MM, Fantuzzi F, Fratter A, et al. Effects of a new nutraceutical formulation (berberine, red yeast rice and chitosan) on non-HDL cholesterol levels in individuals with dyslipidemia: results from a randomized, double blind, placebo-controlled study. Int J Mol Sci. 2017;18(7):1498.

Sundararaman SS, Döring Y, van der Vorst EP. PCSK9: A multi-faceted protein that is involved in cardiovascular biology. Biomedicines. 2021;9(7):793.

Talebi S, Bagherniaya M, Atkin SL, Askari G, Orafai HM, Sahebkar A. The beneficial effects of nutraceuticals and natural products on small dense LDL levels, LDL particle number and LDL particle size: A clinical review. Lipids Health Dis. 2020;19(1):66. doi: 10.1186/s12944-020-01250-6.

Tillhon M, Ortiz LMG, Lombardi P, Scovassi AI. Berberine: new perspectives for old remedies. Biochem Pharmacol. 2012;84:1260-7.

Ting-Ting L, Zhi-Bin W, Yang L, Feng C, Bing-You Y, Kuang H-X. The mechanisms of traditional Chinese medicine underlying the prevention and treatment of atherosclerosis. Chin J Nat Med. 2019;17:401-12.

Toth S, Pella D, Fedacko J. Vaccines targeting PSCK9 for the treatment of hyperlipidemia. Cardiol Ther. 2020;9:323-32.

Vahedian-Azimi A, Mohammadi SM, Beni FH, Banach M, Guest PC, Jamialahmadi T, et al. Improved COVID-19 ICU admission and mortality outcomes following treatment with statins: A systematic review and meta-analysis. Arch Med Sci. 2021;17:579-95. doi: 10.5114/aoms/132950.

Xiao H-B, Sun Z-L, Zhang H-B, Zhang D-S. Berberine inhibits dyslipidemia in C57BL/6 mice with lipopolysaccharide induced inflammation. Pharmacol Rep. 2012;64:889-95.

Yaribeygi H, Jamialahmadi T, Moallem SA, Sahebkar A. Boosting GLP-1 by natural products. Adv Exp Med Biol. 2021;1328:513-522. doi: 10.1007/978-3-030-73234-9_36.

Zhang D-W, Lagace TA, Garuti R, Zhao Z, McDonald M, Horton JD, et al. Binding of proprotein convertase subtilisin/kexin type 9 to epidermal growth factor-like repeat A of proprotein kexin type 9 with epidermal growth factor-like repeat A of low density lipoprotein receptor decreases receptor recycling and increases degradation. J Biol Chem. 2007;282:18602-12.

Zhang J, Zhang Q, Liu G, Zhang N. Therapeutic potentials and mechanisms of the Chinese traditional medicine Danshensu. Eur J Pharmacol. 2019;864:172710.